

First CRISPR Patent for MilliporeSigma

14 June 2017 | News

MilliporeSigma has patent filings for its insertion CRISPR method in Brazil, Canada, China, Europe, India, Israel, Japan, Singapore, South Korea, and the U.S.



Australian Patent Office has granted MilliporeSigma patent rights relating to the use of CRISPR in a genomic integration method for eukaryotic cells.

The patent is the first that MilliporeSigma, a leader in genome editing, has received for CRISPR technology. The patent covers chromosomal integration, or cutting of the chromosomal sequence of eukaryotic cells (such as mammalian and plant cells) and insertion of an external or donor DNA sequence into those cells using CRISPR.

MilliporeSigma has patent filings for its insertion CRISPR method in Brazil, Canada, China, Europe, India, Israel, Japan, Singapore, South Korea, and the U.S.

MilliporeSigma has a 14-year history in the genome-editing field. It was the first company to offer custom biomolecules for genome editing globally driving adoption of these techniques by researchers all over the world. MilliporeSigma was also the first company to manufacture arrayed CRISPR libraries covering the entire human genome, accelerating cures for diseases by allowing scientists to explore more questions about root causes.

With MilliporeSigma's CRISPR genomic integration technology, scientists can replace a disease-associated mutation with a beneficial or functional sequence, a method important for creation of disease models and gene therapy. Additionally, scientists can use the method to insert transgenes that label endogenous proteins for visual tracking within cells.